Famotine

Famotine

SCHEMBL600861

Clc1ccc(OCC2=NCCc3ccccc32)cc1

nearest known ligand 0.47

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.47
KDM4E B2RXH2 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.43
LMNA P02545 1/20 0.43
MAPT P10636 1/20 0.43
HTT P42858 1/20 0.43
PKM P14618 1/20 0.43
NOS3 P29474 1/20 0.41
NOS2 P35228 1/20 0.41
TDP1 Q9NUW8 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
TSHR P16473 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
CYP19A1 P11511 1/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
POLB P06746 1/20 0.39
MAOA P21397 3/20 0.39
MAOB P27338 3/20 0.39
EGFR P00533 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Famotine SCHEMBL147773 0.99 ALDH1A1 (0.46) ALDH1A1KDM4ESMN1; SMN2LMNAMAPT
Famotine SCHEMBL32677713 0.99 ALDH1A1 (0.46) ALDH1A1KDM4ESMN1; SMN2LMNAMAPT
Memotine SCHEMBL29388019 0.86 ALDH1A1 (0.47) ALDH1A1KDM4ESMN1; SMN2LMNAMAPT
Memotine SCHEMBL147540 0.84 PKM (0.48) ALDH1A1KDM4ELMNAMAPTHTT
SCHEMBL28811723 0.78 ALDH1A1 (0.50) ALDH1A1KDM4ELMNAMAPTHTT
SCHEMBL7338667 0.75 KDM4E (0.54) ALDH1A1KDM4ELMNAMAPTPKM
SCHEMBL9815282 0.73 ALDH1A1 (0.58) ALDH1A1KDM4ELMNANOS3NOS2
Hydrochloric Acid SCHEMBL3452241 0.72 KDM4E (0.57) ALDH1A1KDM4ELMNAMAPTNOS3
SCHEMBL29361631 0.71 KDM4E (0.60) ALDH1A1KDM4ELMNAMAPTNOS3
SCHEMBL7509399 0.71 KDM4E (0.60) ALDH1A1KDM4ELMNAMAPTNOS3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 205 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240165086-A1 COATED FAMOTIDINE PARTICLE KENVUE BRANDS LLC 2024-05-23 US claimed
EP-4312992-A1 A PHARMACEUTICAL COMPOSITION COMPRISING FAMOTIDINE JOHNSON & JOHNSON CONSUMER INC. (US) 2024-02-07 EP claimed
WO-2022200897-A1 A PHARMACEUTICAL COMPOSITION COMPRISING FAMOTIDINE JOHNSON & JOHNSON CONSUMER INC. (US) 2022-09-29 WO claimed
US-20210094954-A1 PREPARATION METHODS AND APPLICATIONS OF 3,5-DISUBSTITUTED METHYLPYRAZOLO[1,5-A]PYRIMIDINE-7-HYDROXYLIC SALTS XU LIFENG (US) 2021-04-01 US claimed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 US claimed
US-8637531-B2 Pyrido(3,2-d)pyridmidines useful for treating viral infections GILEAD SCIENCES, INC. (US) 2014-01-28 US claimed
US-8232278-B2 Pyrido(3,2-D)pyrimidines and pharmaceutical compositions useful for treating hepatitis C GILEAD SCIENCES, INC. (US) 2012-07-31 US claimed
US-20120178915-A1 PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF XU LIFENG (US) 2012-07-12 US claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 US claimed
US-20100048559-A1 PYRIDO(3,2-d)PYRIDMIDINES USEFUL FOR TREATING VIRAL INFECTIONS Gilead Science, Inc (US) 2010-02-25 US claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 US claimed
CN-1871203-A Composition comprising phenethyl aryl esters as solubilizers for active organic compounds ISP INVESTMENTS INC (US) 2006-11-29 CN claimed
EP-1608403-A2 IMMUNOSTIMULATORY NUCLEIC ACID OIL-IN-WATER FORMULATIONS FOR TOPICAL APPLICATION Coley Pharmaceutical Group, Ltd. (CA) 2005-12-28 EP claimed
CN-1642530-A Modified release tablet based on microcapsules FLAMEL TECH SA (FR) 2005-07-20 CN claimed
WO-2004087203-A2 IMMUNOSTIMULATORY NUCLEIC ACID OIL-IN-WATER FORMULATIONS FOR TOPICAL APPLICATION COLEY PHARMACEUTICAL GROUP, LTD. (CA) 2004-10-14 WO claimed
EP-1434602-A2 CPG FORMULATIONS AND RELATED METHODS Merial Limited (US) 2004-07-07 EP claimed
CN-1147292-C Double capsule for the administration of active principles in multiple therepies ������ҩ�����޹�˾ 2004-04-28 CN claimed
WO-2003030934-A2 CPG FORMULATIONS AND RELATED METHODS MERIAL LIMITED (US) 2003-04-17 WO claimed
CN-1285741-A Double-layer capsule for administering active ingredients in combination therapy AXCAN PHARMA INC (CA) 2001-02-28 CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210094954-A1 PREPARATION METHODS AND APPLICATIONS OF 3,5-DISUBSTITUTED METHYLPYRAZOLO[1,5-A]PYRIMIDINE-7-HYDROXYLIC SALTS DHPS, NUDT1, DPYD ALDH1A1 346/4885KDM4E 1087/4885SMN1; SMN2 3400/4885
US-20120178915-A1 PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF TYMP, TYMS, ADORA3 ALDH1A1 572/4885KDM4E 3483/4885SMN1; SMN2 1771/4885
US-20100048559-A1 PYRIDO(3,2-d)PYRIDMIDINES USEFUL FOR TREATING VIRAL INFECTIONS PNPO, PLPBP, PDXK ALDH1A1 1288/4885KDM4E 2887/4885SMN1; SMN2 2611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.